Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
107.6%
-
Total 13F principal
-
$560,289,110
-
Principal change
-
+$14,966,110
-
Total reported market value
-
$603,151,800
-
Number of holders
-
40
-
Value change
-
-$105,996,884
-
Number of buys
-
14
-
Number of sells
-
20
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q1 2024
As of 31 Mar 2024,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
40 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$560,289,110
in principal (par value) of the bond.
The largest 10 bondholders included
BRAIDWELL LP, Graham Capital Management, L.P., Linden Advisors LP, WOLVERINE ASSET MANAGEMENT LLC, ARISTEIA CAPITAL, L.L.C., Weiss Asset Management LP, D. E. Shaw & Co., Inc., Voya Investment Management LLC, 683 Capital Management, LLC, and LAZARD ASSET MANAGEMENT LLC.
This page lists
40
institutional bondholders reporting positions
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.